Abstract
In a double-blind, randomized crossover study, the hypotheses were tested that more powerful inhibition of gastric acid secretion by adjuvant omeprazole further improves the efficacy of pancreatic enzyme replacement therapy compared to adjuvant cimetidine and that excluding the influence of pH-related factors, by virtually complete inhibition of gastric acid secretion with 60 mg omeprazole daily, does not lead to total elimination of steatorrhea. During both adjuvant cimetidine and omeprazole treatment, fecal fat excretion was significantly lower compared to pancreatin monotherapy (P<0.01). Omeprazole showed a trend towards a more favorable decrease of fecal fat excretion compared to cimetidine but no statistically significant difference. Steatorrhea was almost never abolished, even during 60 mg omeprazole daily. Generally, pH-related factors are considered to explain an inadequate therapeutic response during pancreatic enzyme replacement therapy. However, this study indicates thatin vivo other factors also play a significant role.
Similar content being viewed by others
References
Heizer WD, Cleaveland CR, Iber FL: Gastric inactivation of pancreatic supplements. Bull Johns Hopkins Hosp 116:261–270, 1965
Regan PT, Malagelada JR, DiMagno EP, Glanzman SL, Go VL: Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med 297:854–858, 1977
DiMagno EP, Malagelada JR, Go VL, Moertel CG: Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N Engl J Med 296:1318–1322, 1977
DiMagno EP: Controversies in the treatment of exocrine pancreatic insufficiency. Dig Dis Sci 27:481–484, 1982
Stead RJ, Skypala I, Hodson ME: Treatment of steatorrhea in cystic fibrosis: A comparison of enteric coated microspheres of pancreatin versus non-enteric coated pancreatin and adjuvant cimetidine. Aliment Pharmacol Ther 2:471–482, 1988
Marotta F, O'Keefe SJD, Marks IN, Girdwood A, Young G: Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating. Dig Dis Sci 34:456–461, 1989
Lankisch PG, Lembcke B, Goke B, Creutzfeldt W: Therapy of pancreatogenic steatorrhoea: Does acid protection of pancreatic enzymes offer any advantage? Z Gastroenterol 24:753–757, 1986
Carroccio A, Pardo F, Montalto G, Iapichino L, Soresi M, Averna MR, Iacono G, Notarbartolo A: Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. Dig Dis Sci 37:1441–1446, 1992
Heijerman HG, Lamers CB, Bakker W: Omeprazole enhances the efficacy of pancreatin (Pancrease) in cystic fibrosis. Ann Intern Med 114:200–201, 1991
Walt RP, Gomes MDFA, Wood EC, Logan LH, Pounder RE: Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 287:12–14, 1983
Naesdal J, Bodemar G, Walan A: Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 19:916–922, 1984
Olbe L, Lind T, Cederberg C, Ekenved G: Effect of omeprazole on gastric acid secretion in man. Scand J Gastroenterol Suppl 21:105–107, 1986
Van de Kamer JH, Bokkel Huinink ten H, Weyers HA: Rapid method for the determination of fat in feces. J Biol Chem 177:347–355, 1949
Andersen JR, Bendtsen F, Ovesen L, Pedersen NT, Rune SJ, Tage Jensen U: Pancreatic insufficiency. Duodenal and jejunal pH, bile acid activity, and micellar lipid solubilization. Int J Pancreatol 6:263–270, 1990
Regan PT, Malagelada JR, DiMagno EP, Go VL: Reduced intraluminal bile acid concentrations and fat maldigestion in pancreatic insufficiency: correction by treatment. Gastroenterology 77:285–289, 1979
Zentler Munro PL, Fine DR, Batten JC, Northfield TC: Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 26:892–901, 1985
Cabral DJ, Small DM: Physical chemistry of bile.In Handbook of Physiology. A Critical, Comprehensive Presentation of Physiological Knowledge and Concepts. Section 6, The Gastrointestinal System. SG Schultz, JG Forte, BB Rauner (eds). Bethesda, American Physiological Society, 1989, pp 621–662
Dutta SK, Anand K, Gadacz TR: Bile salt malabsorption in pancreatic insufficiency secondary to alcoholic pancreatitis. Gastroenterology 91:1243–1249, 1986
Graham DY: Pancreatic enzyme replacement. The effect of antacids or cimetidine. Dig Dis Sci 27:485–490, 1982
Graham DY: Enzyme replacement therapy of exocrine pancreatic insufficiency in man. Relations between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts. N Engl J Med 296:1314–1317, 1977
Bank S, Marks IN, Groll A: Gastric acid secretion in pancreatic disease. Gastroenterology 51:649–655, 1966
Gupta S, Rao TR: Gastric acid secretion in pancreatic disease. Digestion 12:189–191, 1975
Regan PT, Malagelada JR, DiMagno EP, Go VL: Postprandial gastric function in pancreatic insufficiency. Gut 20:249–254, 1979
Saunders JH, Cargill JM, Wormsley KG: Gastric secretion of acid in patients with pancreatic disease. Digestion 17:365–369, 1978
Cox KL, Isenberg JN: Hypersecretion of gastric acid in patients with pancreatic exocrine insufficiency due to cystic fibrosis. Gastroenterology 74:1022, 1978
Gullo L, Corinaldesi R, Casadio R, Vezzadini P, Tomassetti P, Ventrucci M, Priori P, Labo G: Gastric acid secretion in chronic pancreatitis. Hepato-Gastroenterol 30:60–62, 1983
Dutta SK, Russell RM, Iber FL: Influence of exocrine pancreatic insufficiency on the intraluminal pH of the proximal small intestine. Dig Dis Sci 24:529–534, 1979
Ovesen L, Bendtsen F, Tage Jensen U, Pedersen NT, Gram BR, Rune SJ: Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 90:958–962, 1986
Lankisch PG, Lembcke B, Wemken G, Creutzfeldt W: Functional reserve capacity of the exocrine pancreas. Digestion 35:175–181, 1986
Thiruvengadam R, DiMagno EP: Inactivation of human lipase by proteases. Am J Physiol 255 (Gastrointest Liver Physiol 18):G476-G481, 1988
Thiruvengadam R, Sandberg R, Bentley K, DiMagno EP: Why does lipase activity decrease during aboral small intestinal transit in humans? Gastroenterology 90:1663, 1986 (abstract)
Borgström B, Erlanson C: Pancreatic juice co-lipase. Physiological importance. Biochim Biophys Acta 242:509–513, 1971
Kelly DG, Bentley KJ, Sarles H, Zinsmeister AR, DiMagno EP: Do nutrients and bile in human duodenal juice affect the survival of lipase activity? Possible clinical implications. Gastroenterology 94:A222, 1988 (abstract)
Dutta SK, Hlasko J: Dietary fiber in pancreatic disease. Effect of high fiber diet on fat malabsorption in pancreatic insufficiency andin vitro study of the interaction of dietary fiber with pancreatic enzymes. Am J Clin Nutr 41:517–525, 1985
Morin CL, Roy CC, Lasalle R, Bonin A: Small bowel mucosal dysfunction in patients with cystic fibrosis. J Pediatr 88:213–216, 1976
Abrams CK, Hamosh M, Dutta SK, Hubbard VS, Hamosh P: Role of nonpancreatic lipolytic activity in exocrine pancreatic insufficiency. Gastroenterology 92:125–129, 1987
Moreau J, Bouisson M, Balas D, Ravaud A, Stupnik S, Buscail L, Vaysse N, Ribet A: Gastric lipase in alcoholic pancreatitis. Comparison of secretive profiles following pentagastrin stimulation in normal adults and patients with pancreatic insufficiency. Gastroenterology 99:175–180, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bruno, M.J., Rauws, E.A.J., Hoek, F.J. et al. Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. Digest Dis Sci 39, 988–992 (1994). https://doi.org/10.1007/BF02087549
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02087549